FDA grants full approval to AbbVie’s ovarian cancer drug ELAHERE
AbbVie (NYSE: ABBV) has achieved a significant milestone in the fight against ovarian cancer with the U.S. Food and Drug Administration (FDA) granting full approval for ELAHERE (mirvetuximab soravtansine-gynx), marking a major advancement for patients suffering from this challenging condition. ELAHERE is designed to treat folate receptor alpha (FRα)-positive, platinum-resistant epithelial ovarian, fallopian tube, or […]